Breast Cancer: Medications for Risk Reduction
Release Date: September 2013
Summary of Recommendations and Evidence
|Women, Increased Risk for Breast Cancer|
The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene.
|The USPSTF recommends the service. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.|
|Women, Not at Increased Risk for Breast Cancer|
The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer.
|The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits|
Go to the Clinical Considerations for additional information about risk factors.
Related Information for Health Professionals
- Breast Cancer Risk Assessment Tool from the National Cancer Institute
- Medications for Risk Reduction of Primary Breast Cancer in Women - Clinical Summary of USPSTF Recommendation, 2013
- Cancer Control P.L.A.N.E.T.
- Recommendations from The Community Preventive Services Task Force on Promoting Cancer Screening
Internet Citation: Recommendation Summary. U.S. Preventive Services Task Force. September 2014.